Zusammenfassung
Hintergrund: Besonders okkulte choroidale Neovaskularisationen (CNV) mit Pigmentepithelabhebung (PED) zeigen nach Standard-PDT oft eine Vergrößerung der PED oder einen RPE-Riss. Untersucht wird der Effekt einer Kombination von photodynamischer Therapie (PDT) und intravitrealer Behandlung mit Bevacizumab bei okkulter und klassischer choroidaler Neovaskularisation (CNV) bei AMD. Methoden: In einer Pilotstudie wurden 23 Patienten mit okkulter oder klassischer CNV bei AMD mit intravitrealer Injektion von Bevacizumab (1,25 mg) 12 bis 24 Stunden nach Standard-PDT behandelt. Vor, 1, 3 und 6 Monate nach Behandlung wurden Sehschärfe und mit dem OCT die Netzhautdicke untersucht. Ergebnisse: Die mittlere Sehschärfe verbesserte sich im Vergleich zur Ausgangssehschärfe signifikant. (Visus vor Behandlung = 0,16, nach 1 Monat 0,26, nach 3 Monaten 0,25 und 0,25 nach 6 Monaten). Wir fanden keinen RPE-Riss. Die OCT-Untersuchung 1, 3 and 6 Monate nach Kombinationstherapie zeigte eine Reduktion der Netzhautdicke. Schlussfolgerung: Eine photodynamische Therapie kombiniert mit intravitrealer Applikation von Bevacizumab scheint aufgrund des Anti-VEGF- und des antientzündlichen Effektes von Bevacizumab wirksamer zu sein als eine PDT-Monotherapie. Unsere Kurzzeitergebnisse sind vielversprechend. Weitere Untersuchungen sind nötig, um den Langzeiteffekt der Kombinationstherapie von PDT und intravitrealer Anti-VEGF-Therapie zu überprüfen.
Abstract
Purpose: The aim of this study is to discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab (1.25 mg) in occult and classic choroidal neovascularisation (CNV) due to AMD. Especially cases of occult CNV with pigment epithelium detachment (PED) are not likely to respond positively to standard photodynamic therapy, often ending up in PED enlargement or tearing of the RPE. Methods: In a pilot study involving 23 patients, intravitreal injections of bevacizumab were administered within 12 to 24 hours after standard PDT to reduce the post-PDT increase of proangiogenic and inflammatory factors. Before and at 1, 3 and 6 month after treatment visual acuity and OCT examinations (retinal thickness) were performed. Results: Mean visual acuity was significantly improved compared to baseline. (VA baseline 20 / 125, after 1 month 20 / 80, after 3 months 20 / 80, and 20 / 80 after 6 months) and an enlargement of the PED in occult CNV was prevented. We found no RPE rip. OCT findings in patients with occult and classic choroidal neovascularisation 1, 3 and 6 months after combination therapy showed a reduced retinal thickness compared to baseline. Conclusions: Photodynamic therapy combined with injection of intravitreal bevacizumab tends to be more effective compared to PDT monotherapy by reducing the post-PDT increase of vascular growth and inflammatory factors. Our short-term results are very promising. Further studies are necessary to show the long-term effect of PDT and anti-VEGF combination therapy.
Schlüsselwörter
Retina - Glaskörper - Chorioidea
Key words
retina - vitreous - choroid
Literatur
1
Aiello L P, Brucker A J, Chang S. et al .
Evolving guidelines for intravitreous injections.
Retina.
2004;
24
S3-S19
2
Augustin A J, Schmidt-Erfurth U.
Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
Ophthalmology.
2006;
113
14-22
3
Avery R L, Pieramici D J, Rabena M D. et al .
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Ophthalmology.
2006;
113
363-372
4
Bernatchez P N, Rollin S, Soker S. et al .
Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1.
J Cell Biochem.
2002;
85
629-639
5
Blinder K J, Bradley S, Bressler N M. et al .
Effekt of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choridal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
Am J Ophthalmol.
2003;
136
407-418
6
Brown D M, Kaiser P K, Michels M. et al .
ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med.
2006;
355 (14)
1432-1444
7
Costa R A, Jorge R, Calucci D. et al .
Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IbeVe Study).
Graefes Arch Clin Exp Ophthalmol.
2007;
245 (9)
1273-1280
8
Dhalla M S, Shah G K, Blinder K J. et al .
Combined photodynamic therapy with verteporfin and intravitreal bevazicumab for choroidal neovascularization in age-related macular degeneration.
Retina.
2006;
26 (9)
988-993
9
Goldstein M, Heilweil G, Barak A. et al .
Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD.
Eye.
2005;
19 (12)
1315-1324
10
Gragoudas E S, Adamis A P, Cunningham E T Jr. et al .
VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration.
N Engl J Med.
2004;
351 (27)
2805-2816
11
Heier J S, Boyer D S, Ciulla T A. et al .
FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
Arch Ophthalmol.
2006;
124 (11)
1532-1542
12
Heier J S, Antoszyk A N, Pavan P R. et al .
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Ophthalmology.
2006;
113
633. e1–e4. Epub 2006 Feb. 14
13
Hussain D, Kramer M, Kenny A G. et al .
Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment.
Invest Ophthalmol Vis Sci.
1999;
40
2322-2331
14
Hussain D, Kim I, Gauthier D. et al .
Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.
Arch Ophthalmol.
2005;
123
509-516
15
Jaissle G B, Szurman P, Bartz-Schmidt K U.
Recommendation for implementation of intravitreal injections – statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German professional Association of Ophthalmologists (BVA).
Klin Monatsbl Augenheilkd.
2005;
222
390-395
16
Jonas J B.
Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovasular diseases.
Acta Ophthamol Scand.
2005;
83
645-663
17
Kim I K, Husain D, Michaud N. et al .
Effekt of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid.
Invest Ophthalmol Vis Sci.
2006;
47
357-363
18
Kramer M, Miller J W, Michaud N. et al .
Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.
Ophthalmology.
1996;
103
427-438
19
Lazic R, Gabric N, Dekaris I. et al .
Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration.
Coll Antropol.
2007;
31 (Suppl 1)
71-75
20
Ladewig M S, Karl S E, Hamelmann V. et al .
Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol.
2008;
246 (1)
17-25
21
Michels S, Hansmann F, Geitzenauer W. et al .
Influence of treatment parameters on selectivity of verteporfin therapy.
Invest Ophthalmol Vis Sci.
2006;
47
371-376
22
Michels S, Rosenfeld P J, Puliafito C A. et al .
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study.
Ophthalmology.
2005;
112
1035-1047
23
Moshfegi D M, Kaiser P K, Grossniklaus H E. et al .
Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapie.
Am J Ophthalmol.
2003;
135
343-350
24
Rechtman E, Danis R P, Pratt L M. et al .
Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration.
Br J Ophthalmol.
2004;
88
344-347
25
Rosenfeld P J, Moshfeghi A A, Puliafito C A.
Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration.
Ophthalmic Surg Lasers Imaging.
2005;
36
331-335
26
Rosenfeld P J, Brown D M, Heier J S. et al .
MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration.
N Engl J Med.
2006;
355 (14)
1419-1431
27
Rosenfeld P J, Rich R M, Lalwani G A.
Ranibizumab: Phase III clinical trial results.
Ophthalmol Clin North Am.
2006;
19 (3)
361-372
28 PROTECT Data on file.
29
Schmidt-Erfurth U, Miller J W, Sickenberg M. et al .
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Arch Ophthalmol.
1999;
117
1177-1187
30
Schmidt-Erfurth U, Hassan T.
Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.
Surv Ophthalmol.
2000;
45 (3)
195-214
31
Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U. et al .
Histopathological changes following photodynamic therapy in human eyes.
Arch Ophthalmol.
2002;
120
835-844
32
Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C. et al .
Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.
Invest Ophthalmol Vis Sci.
2003;
44
4473-4480
33
Spaide R F, Sorenson J, Maranan L.
Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
Ophthamology.
2003;
110
1517-1525
34
Spaide R F, Sorenson J, Maranan L.
Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.
Ophthalmology.
2005;
112
301-304
35
Spaide R F, Laud K, Fine H F. et al .
Intravitreal bevazicumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Retina.
2006;
26
383-390
36
Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration.
Klin Monatsbl Augenheilkd.
2007;
224 (7)
559-566
37
TAP Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group .
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials-TAP Report 2.
Arch Ophthalmol.
2002;
119
198-207
38
Thakker G D, Hajjar D P, Muller W A. et al .
The role of phospatidylinositol 3-kinase in vascular endothelial growth factor signaling.
J Biol Chem.
1999;
274
10 002-10 007
39
Tzekov R, Lin T, Zhang K M. et al .
Ocular changes after photodynamic therapy.
Invest Ophthalmol Vis Sci.
2006;
47 (1)
377-385
40
Chakravarthy U, Adamis A P, Cunningham E T Jr. et al .
VEGF Inhibition Study in Ocular Neovascularization (V. I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
Ophthalmology.
2006;
113 (9)
1508.e1 – 25. Epub 7.7.2006
Dr. med. Mathias Martin Maier
Klinik und Poliklinik für Augenheilkunde rechts der Isar der Technischen Universität München
Ismaningerstr. 22
81675 Munich
Phone: ++ 49/89/41 40 23 40
Fax: ++ 49/89/41 40 48 58
Email: M.Maier@lrz.tum.de